Otros idiomas Takeda Pharmaceutical Company Limited Fukuoka Stock Exchange

Acciones

4502

JP3463000004

Mercado cerrado - Fukuoka Stock Exchange Otros sitios de cotización 02:25:26 17/04/2024			Varia. Cinco días.	Varia. 1 de enero.
4.080 ^JPY	-1,21 %		-.--%	+2,13 %

04:30	Takeda presenta los últimos datos del estudio de fase 2b de mezagitamab, que demuestran su potencial para transformar el tratamiento de la trombocitopenia inmune primaria	CI
21/06	Takeda obtiene la aprobación de la Comisión Europea para el fármaco Fruzaqla contra el cáncer colorrectal	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	04:30
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	21/06
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment	21/06
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer	21/06
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	21/06
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older	21/06
Les sorcières épouvantent l'IA	21/06
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	21/06
En Direct des Marchés : LVMH, Accor, Alstom, Atos, Casino, Plastivaloire, Boeing, Geberit...	21/06
Borsa di Italia: Le streghe terrorizzano l'AI	21/06
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	21/06
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	21/06
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India	21/06
Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (PIDC)	19/06
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	19/06
Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung	19/06
Ovid Therapeutics Reports on Takeda s Announcement of Phase 3 Topline Study Results for Soticlestat	18/06
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	18/06
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting	18/06
Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	18/06

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Takeda Pharmaceutical Company Limited Fukuoka Stock Exchange

Acciones

4502

JP3463000004

Otros idiomas

Filtros